Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - tryptophan, quantity: 1.9 g/l; arginine, quantity: 11.3 g/l; phenylalanine, quantity: 7.9 g/l; cysteine, quantity: 0.56 g/l; tyrosine, quantity: 0.23 g/l; glycine, quantity: 7.9 g/l; threonine, quantity: 5.6 g/l; methionine, quantity: 5.6 g/l; leucine, quantity: 7.9 g/l; alanine, quantity: 16 g/l; isoleucine, quantity: 5.6 g/l; aspartic acid, quantity: 3.4 g/l; lysine acetate, quantity: 12.7 g/l (equivalent: lysine, qty 9 g/l); serine, quantity: 4.5 g/l; histidine, quantity: 6.8 g/l; proline, quantity: 6.8 - injection, intravenous infusion - excipient ingredients: glacial acetic acid; water for injections - intravenous supply of amino acids specially to patients with highly increased requirement who are unable to receive sufficient amounts of protein enterally. vamin 18 is also indicated where there is a need to control the total amount of fluid being given to a patient.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - cysteine, quantity: 0.42 g/l; leucine, quantity: 5.9 g/l; tryptophan, quantity: 1.4 g/l; isoleucine, quantity: 4.2 g/l; alanine, quantity: 12 g/l; tyrosine, quantity: 0.17 g/l; histidine, quantity: 5.1 g/l; serine, quantity: 3.4 g/l; lysine acetate, quantity: 9.5 g/l (equivalent: lysine, qty 6.8 g/l); aspartic acid, quantity: 2.5 g/l; valine, quantity: 5.5 g/l; phenylalanine, quantity: 5.9 g/l; glycine, quantity: 5.9 g/l; methionine, quantity: 4.2 g/l; arginine, quantity: 8.4 g/l; threonine, quantity: 4.2 g - injection, intravenous infusion - excipient ingredients: water for injections; glacial acetic acid - intravenous supply of amino acids to patients with moderately increased requirement who are unable to receive sufficient amounts of protein enterally

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - alanine, quantity: 12 g/l; glutamic acid, quantity: 4.2 g/l; calcium, quantity: 5 mmol/l; lysine hydrochloride, quantity: 8.5 g/l (equivalent: lysine, qty 6.8 g/l); aspartic acid, quantity: 2.5 g/l; tryptophan, quantity: 1.4 g/l; leucine, quantity: 5.9 g/l; potassium, quantity: 50 mmol/l; serine, quantity: 3.4 g/l; sulfate, quantity: 8 mmol/l; acetate, quantity: 135 mmol/l; methionine, quantity: 4.2 g/l; glycine, quantity: 5.9 g/l; cysteine hydrochloride, quantity: 0.61 g/l (equivalent: cysteine, qty 0.42 g - injection, intravenous infusion - excipient ingredients: water for injections - intravenous supply of amino acids to patients with moderately increased requirement who are unable to receive sufficient amounts of protein enterally.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - cysteine, quantity: 0.42 g/l; lysine acetate, quantity: 9.5 g/l (equivalent: lysine, qty 6.8 g/l); threonine, quantity: 4.2 g/l; proline, quantity: 5.1 g/l; serine, quantity: 3.4 g/l; glutamic acid, quantity: 4.2 g/l; isoleucine, quantity: 4.2 g/l; arginine, quantity: 8.4 g/l; methionine, quantity: 4.2 g/l; phenylalanine, quantity: 5.9 g/l; glycine, quantity: 5.9 g/l; histidine, quantity: 5.1 g/l; alanine, quantity: 12 g/l; tyrosine, quantity: 0.17 g/l; tryptophan, quantity: 1.4 g/l; aspartic acid, quantity - injection, intravenous infusion - excipient ingredients: water for injections; glacial acetic acid - intravenous supply of amino acids to patients with moderately increased requirement who are unable to receive sufficient amounts of protein enterally

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - valine, quantity: 7.3 g/l; leucine, quantity: 7.9 g/l; lysine acetate, quantity: 12.7 g/l (equivalent: lysine, qty 9 g/l); glutamic acid, quantity: 5.6 g/l; threonine, quantity: 5.6 g/l; glycine, quantity: 7.9 g/l; aspartic acid, quantity: 3.4 g/l; tyrosine, quantity: 0.23 g/l; phenylalanine, quantity: 7.9 g/l; isoleucine, quantity: 5.6 g/l; arginine, quantity: 11.3 g/l; alanine, quantity: 16 g/l; serine, quantity: 4.5 g/l; proline, quantity: 6.8 g/l; cysteine, quantity: 0.56 g/l; histidine, quantity: 6.8 g - injection, intravenous infusion - excipient ingredients: glacial acetic acid; water for injections - intravenous supply of amino acids specially to patients with highly increased requirement who are unable to receive sufficient amounts of protein enterally. vamin 18 is also indicated where there is a need to control the total amount of fluid being given to a patient.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - alanine, quantity: 16 g/l; glycylglutamine monohydrate, quantity: 30.27 g/l (equivalent: glutamine, qty 20 g); histidine, quantity: 6.8 g/l; methionine, quantity: 5.6 g/l; tryptophan, quantity: 1.9 g/l; threonine, quantity: 5.6 g/l; lysine acetate, quantity: 12.7 g/l (equivalent: glycine, qty 10.27 g; equivalent: lysine, qty 9 g); valine, quantity: 7.3 g/l; arginine, quantity: 11.3 g/l; glycyltyrosine dihydrate, quantity: 3.45 g/l (equivalent: tyrosine, qty 2.28 g; equivalent: glycine, qty 0.94 g); serine, quantity: 4.5 g/l; proline, quantity: 6.8 g/l; glutamic acid, quantity: 5.6 g/l; leucine, quantity: 7.9 g/l; isoleucine, quantity: 5.6 g/l; aspartic acid, quantity: 3.4 g/l; phenylalanine, quantity: 5.85 g/l - injection, intravenous infusion - excipient ingredients: water for injections; citric acid - glamin provides amino acids as part of parenteral nutrition therapy, when oral or enteral nutrition is impossible, insufficient or contraindicated especially in patients with a moderate or severe catabolic status.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - proline, quantity: 6.8 g/l; isoleucine, quantity: 5.6 g/l; methionine, quantity: 5.6 g/l; lysine acetate, quantity: 12.7 g/l (equivalent: lysine, qty 9 g; equivalent: glycine, qty 10.27 g); serine, quantity: 4.5 g/l; glycylglutamine monohydrate, quantity: 30.27 g/l (equivalent: glycine, qty 10.27 g; equivalent: glutamine, qty 20 g); alanine, quantity: 16 g/l; histidine, quantity: 6.8 g/l; glutamic acid, quantity: 5.6 g/l; tryptophan, quantity: 1.9 g/l; leucine, quantity: 7.9 g/l; valine, quantity: 7.3 g/l; aspartic acid, quantity: 3.4 g/l; phenylalanine, quantity: 5.85 g/l; glycyltyrosine dihydrate, quantity: 3.45 g/l (equivalent: tyrosine, qty 2.28 g; equivalent: glycine, qty 0.94 g); arginine, quantity: 11.3 g/l; threonine, quantity: 5.6 g/l - injection, intravenous infusion - excipient ingredients: citric acid; water for injections - glamin provides amino acids as part of parenteral nutrition therapy, when oral or enteral nutrition is impossible, insufficient or contraindicated especially in patients with a moderate or severe catabolic status.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - soya oil, quantity: 200 mg/ml - injection, emulsion - excipient ingredients: water for injections; egg lecithin; sodium hydroxide; glycerol - parenteral nutrition for patients when oral or enteral nutrition is impossible or insufficient or contraindicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - soya oil, quantity: 200 mg/ml - injection, emulsion - excipient ingredients: sodium hydroxide; egg lecithin; glycerol; water for injections - parenteral nutrition for patients when oral or enteral nutrition is impossible or insufficient or contraindicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - alanine,arginine,aspartic acid,calcium chloride dihydrate,glucose monohydrate,glutamic acid,glycine,histidine,isoleucine,leucine,lysine hydrochloride,magnesium sulfate heptahydrate,methionine,phenylalanine,potassium chloride,proline,serine,sodium acetate trihydrate,sodium glycerophosphate,soya oil,threonine,tryptophan,tyrosine,valine -